438 related articles for article (PubMed ID: 35717322)
1. Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer.
Heidegger I; Fotakis G; Offermann A; Goveia J; Daum S; Salcher S; Noureen A; Timmer-Bosscha H; Schäfer G; Walenkamp A; Perner S; Beatovic A; Moisse M; Plattner C; Krogsdam A; Haybaeck J; Sopper S; Thaler S; Keller MA; Klocker H; Trajanoski Z; Wolf D; Pircher A
Mol Cancer; 2022 Jun; 21(1):132. PubMed ID: 35717322
[TBL] [Abstract][Full Text] [Related]
2. Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice.
Saha A; Ahn S; Blando J; Su F; Kolonin MG; DiGiovanni J
Cancer Res; 2017 Sep; 77(18):5158-5168. PubMed ID: 28687617
[TBL] [Abstract][Full Text] [Related]
3. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
Hsiao JJ; Ng BH; Smits MM; Wang J; Jasavala RJ; Martinez HD; Lee J; Alston JJ; Misonou H; Trimmer JS; Wright ME
BMC Cancer; 2015 Mar; 15():204. PubMed ID: 25884570
[TBL] [Abstract][Full Text] [Related]
5. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR
Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator‑activated receptor γ agonist rosiglitazone inhibits migration and invasion of prostate cancer cells through inhibition of the CXCR4/CXCL12 axis.
Qin L; Gong C; Chen AM; Guo FJ; Xu F; Ren Y; Liao H
Mol Med Rep; 2014 Aug; 10(2):695-700. PubMed ID: 24842333
[TBL] [Abstract][Full Text] [Related]
7. CXCL12 mediates trophic interactions between endothelial and tumor cells in glioblastoma.
Rao S; Sengupta R; Choe EJ; Woerner BM; Jackson E; Sun T; Leonard J; Piwnica-Worms D; Rubin JB
PLoS One; 2012; 7(3):e33005. PubMed ID: 22427929
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
9. CXCR4 and CXCL12 (SDF-1) in prostate cancer: inhibitory effects of human single chain Fv antibodies.
Vaday GG; Hua SB; Peehl DM; Pauling MH; Lin YH; Zhu L; Lawrence DM; Foda HD; Zucker S
Clin Cancer Res; 2004 Aug; 10(16):5630-9. PubMed ID: 15328206
[TBL] [Abstract][Full Text] [Related]
10. A pro-tumourigenic loop at the human prostate tumour interface orchestrated by oestrogen, CXCL12 and mast cell recruitment.
Ellem SJ; Taylor RA; Furic L; Larsson O; Frydenberg M; Pook D; Pedersen J; Cawsey B; Trotta A; Need E; Buchanan G; Risbridger GP
J Pathol; 2014 Sep; 234(1):86-98. PubMed ID: 25042571
[TBL] [Abstract][Full Text] [Related]
11. SLUG promotes prostate cancer cell migration and invasion via CXCR4/CXCL12 axis.
Uygur B; Wu WS
Mol Cancer; 2011 Nov; 10():139. PubMed ID: 22074556
[TBL] [Abstract][Full Text] [Related]
12. AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer.
Zhu WB; Zhao ZF; Zhou X
J Cell Physiol; 2019 Jul; 234(7):11746-11759. PubMed ID: 30537000
[TBL] [Abstract][Full Text] [Related]
13. Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies.
Baci D; Bruno A; Cascini C; Gallazzi M; Mortara L; Sessa F; Pelosi G; Albini A; Noonan DM
J Exp Clin Cancer Res; 2019 Nov; 38(1):464. PubMed ID: 31718684
[TBL] [Abstract][Full Text] [Related]
14. Chemokine CXCL12 and its receptor CXCR4 expression are associated with perineural invasion of prostate cancer.
Zhang S; Qi L; Li M; Zhang D; Xu S; Wang N; Sun B
J Exp Clin Cancer Res; 2008 Nov; 27(1):62. PubMed ID: 18983683
[TBL] [Abstract][Full Text] [Related]
15. The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis.
Arya M; Patel HR; McGurk C; Tatoud R; Klocker H; Masters J; Williamson M
J Exp Ther Oncol; 2004 Dec; 4(4):291-303. PubMed ID: 15844659
[TBL] [Abstract][Full Text] [Related]
16. Chemokine receptor CXCR4: role in gastrointestinal cancer.
Lombardi L; Tavano F; Morelli F; Latiano TP; Di Sebastiano P; Maiello E
Crit Rev Oncol Hematol; 2013 Dec; 88(3):696-705. PubMed ID: 24120239
[TBL] [Abstract][Full Text] [Related]
17. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo.
Sun YX; Wang J; Shelburne CE; Lopatin DE; Chinnaiyan AM; Rubin MA; Pienta KJ; Taichman RS
J Cell Biochem; 2003 Jun; 89(3):462-73. PubMed ID: 12761880
[TBL] [Abstract][Full Text] [Related]
18. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
Liu Y; Ren CC; Yang L; Xu YM; Chen YN
J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
[TBL] [Abstract][Full Text] [Related]
19. Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro.
Frigo DE; Sherk AB; Wittmann BM; Norris JD; Wang Q; Joseph JD; Toner AP; Brown M; McDonnell DP
Mol Endocrinol; 2009 Sep; 23(9):1385-96. PubMed ID: 19460858
[TBL] [Abstract][Full Text] [Related]
20. CXCL12/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1.
Bhardwaj A; Srivastava SK; Singh S; Arora S; Tyagi N; Andrews J; McClellan S; Carter JE; Singh AP
Oncotarget; 2014 Nov; 5(22):11490-500. PubMed ID: 25359780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
